Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Mobil beredskapshåndtering for røykeslutt (P3)

27. oktober 2026 oppdatert av: University of Oklahoma

Mobil beredskapshåndtering for røykeslutt blant sosioøkonomisk vanskeligstilte voksne

The purpose of the proposed project is to evaluate an automated mobile phone-based CM approach that will allow socioeconomically disadvantaged individuals to remotely benefit from financial incentives for smoking cessation. The investigators have previously combined technologies including 1) portable carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to confirm participant identity during breath sample submissions, and 3) remote delivery of incentives automatically triggered by biochemical confirmation of self-reported abstinence. This automated CM approach will be evaluated in a randomized controlled trial that includes 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to either telephone counseling and nicotine replacement therapy (standard care [SC]) or SC plus a mobile financial incentives intervention (CM) for biochemically-confirmed abstinence. Participants will be followed for 26 weeks after a scheduled quit attempt. Biochemically-verified 7-day point prevalence abstinence at 26 weeks post-quit will be the primary outcome variable. Cost-effectiveness will be evaluated to inform policy-related decisions. Potential mobile CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement, will be explored to optimize future versions of the intervention.

Studieoversikt

Detaljert beskrivelse

The primary purpose of the proposed project is to evaluate an automated smartphone-based CM approach that will allow socioeconomically disadvantaged adults to earn financial incentives for smoking cessation without requiring in-person attendance for abstinence verification. The investigators have combined technologies: 1) low-cost carbon monoxide monitors that connect with mobile phones to remotely verify smoking abstinence, 2) facial recognition software to verify the identity of participants while they provide a breath sample, and 3) remote and automated delivery of incentives to a credit card triggered by biochemical confirmation of self-reported smoking abstinence. This CM approach will be evaluated in a randomized controlled trial of 532 socioeconomically disadvantaged males and females seeking smoking cessation treatment. Participants will be randomly assigned to telephone counseling plus nicotine replacement therapy (standard care [SC]) or SC plus a 12-week smartphone-based financial incentives intervention (CM). Participants will be followed for 26 weeks after a scheduled quit attempt, which is 14 weeks after incentives have ended. Cost-effectiveness will be evaluated to inform policy and health care decisions. Potential CM treatment mechanisms, including self-efficacy, motivation, and treatment engagement will be identified to optimize future versions of the intervention. The specific aims are: 1) to evaluate the impact of an automated, mobile phone-based CM approach relative to SC on smoking cessation among socioeconomically disadvantaged adults, 2) to compare the cost-effectiveness of two smoking cessation interventions (CM vs. SC), and 3) to identify mobile CM treatment mechanisms such as motivation to quit, self-efficacy for quitting, and treatment engagement/adherence. The proposed study will evaluate an intervention approach that increases the reach of a potentially effective and cost-effective smoking cessation intervention for socioeconomically disadvantaged smokers. This proposed study is also going to be conducting recruitment nationwide.

Studietype

Intervensjonell

Registrering (Faktiske)

532

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Oklahoma
      • Oklahoma City, OK, Oklahoma, Forente stater, 73104
        • TSET Health Promotion Research Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. report an annual household income of <200% of the federal poverty threshold (i.e., low-income)
  2. earn a score ≥4 on the REALM indicating >6th grade English literacy level (i.e., a 7th grade reading level is necessary to complete assessments)
  3. are willing to quit smoking 7-14 days after enrollment
  4. are ≥ 18 years of age
  5. currently smoke ≥ 5 cigarettes per day
  6. have a CO level of >6 ppm
  7. are willing to abstain from smoking cannabis and other combustible tobacco products (they raise CO levels and mask cigarette abstinence)
  8. have no contraindications for NRT
  9. Provide a copy/photo of driver's license or other documentation as proof of identity and U.S. residence

Exclusion Criteria

1) do not meet the specified inclusion criteria

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Standard Care (SC)

Participants randomized to Standard Care will be offered weekly smoking cessation counseling and pharmacotherapy.

Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)

Eksperimentell: Contingency Management (CM)

CM participants will receive standard care in addition to small financial incentives for biochemically-verified abstinence.

Tobacco cessation telephone counseling and combination nicotine replacement therapy (nicotine patches + nicotine gum/lozenges)

Financial incentives contingent upon smoking abstinence

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 26 weeks post-quit-date

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 26 weeks post-quit.

26 weeks post-quit-date

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Cost-effectiveness
Tidsramme: 26 weeks post-quit-date

The incremental cost effectiveness ratio (ICER) calculated as the difference in mean costs between the new (CM) and standard treatment (SC) divided by the difference in mean effectiveness between the two, estimates additional resources needed to achieve an increase of one unit of effectiveness. The ICER is then compared with published threshold values for cost-effective interventions. The cost model will include all necessary personnel, hardware, and material costs.

26 weeks post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 12 week post-quit-date

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 12 weeks post-quit-date.

12 week post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 8 weeks post-quit-date

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 8 weeks post-quit-date.

8 weeks post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 7 Days)
Tidsramme: 4 weeks post-quit-date

Number of participants with carbon monoxide-verified 7-day point prevalence abstinence at 4 weeks post-quit-date.

4 weeks post-quit-date
Carbon Monoxide-Verified Smoking Abstinence (Past 30 Days)
Tidsramme: 26 weeks post-quit-date

Number of participants with carbon monoxide-verified 30-day point prevalence abstinence at 26 weeks post-quit-date.

26 weeks post-quit-date

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Darla E. Kendzor, PhD, University of Oklahoma

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. november 2022

Primær fullføring (Faktiske)

21. september 2025

Studiet fullført (Faktiske)

21. september 2025

Datoer for studieregistrering

Først innsendt

29. mars 2021

Først innsendt som oppfylte QC-kriteriene

5. mai 2021

Først lagt ut (Faktiske)

11. mai 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified data will be made available to investigators upon request, after publication of the primary study findings, and with a data-sharing agreement that specifies the investigator(s) will 1) use the data only for research purposes and not to identify any individual participant, 2) store the data on a secure device (e.g., encrypted, password-protected), and 3) destroy or return the data after completion of the analyses.

IPD-delingstidsramme

De-identified data will be made available to investigators upon request after publication of the primary study findings.

Tilgangskriterier for IPD-deling

Data sharing agreement

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • ICF

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere